GSK partnership deal signals further intent on cancer 25-Feb-2020 By Ben Hargreaves The company signs a deal with Immatics for the development of TCR therapeutics targeting solid tumors.
Celgene signs $1.5bn deal with Immatics for ‘key’ to treat solid tumors 28-Aug-2019 By Ben Hargreaves Celgene agrees option to acquire rights to three TCR-T therapies from Immatics, with the aim of developing potential treatments for solid tumors.